HopeStage
Back to all studies
CompletedNCT02139124

PRC-063 Compared With Placebo for ADHD in Adults

About this titleRead the official source — NCT02139124

Researchers compared PRC-063 25 mg, placebo, PRC-063 45 mg, PRC-063 70 mg and PRC-063 100 mg, tracking side effects to assess safety in adults with ADHD.

Medication studyAges 18+United States + Canada
The study in practice

Understand this study

What did researchers investigate?

Researchers compared PRC-063 25 mg, placebo, PRC-063 45 mg, PRC-063 70 mg and PRC-063 100 mg, tracking side effects to assess safety in adults with ADHD.

Who was this study for?

Listed age limits: from 18 years.

Listed locations
Los Angeles and 37 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateApril 2014
Recruitment status
Completed
Enrollment listed in the registry
375
Sponsor
Rhodes Pharmaceuticals, L.P.
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Canada
Age range
Over 18 Years
Official registry ID
NCT02139124
Official title
Show the full official title

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Multi-Center Study Measuring the Efficacy and Safety of PRC-063 in Adult ADHD Patients

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Los Angeles, United States · National City, United States · Newport Beach, United States

32 more locations
  • Orange, United States
  • Bradenton, United States
  • Gainesville, United States
  • Jacksonville, United States
  • Maitland, United States
  • Orlando, United States
  • Tampa, United States
  • Boise, United States
  • Las Vegas, United States
  • Princeton, United States
  • New York, United States
  • Raleigh, United States
  • Cincinnati, United States
  • Oklahoma City, United States
  • Portland, United States
  • Salem, United States
  • Memphis, United States
  • Austin, United States
  • Dallas, United States
  • Houston, United States
  • Lubbock, United States
  • Clinton, United States
  • Salt Lake City, United States
  • Woodstock, United States
  • Herndon, United States
  • Bellevue, United States
  • Kirkland, United States
  • Vancouver, Canada
  • Niagara Falls, Canada
  • Ottawa, Canada
  • Whitby, Canada
  • Sherbrooke, Canada

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers compared PRC-063 25 mg, placebo, PRC-063 45 mg, PRC-063 70 mg and PRC-063 100 mg, tracking side effects to assess safety in adults with ADHD.

Who is behind this study?

The study sponsor is Rhodes Pharmaceuticals, L.P.

Did this study involve medication?

Yes. The study involved medication, including Placebo, PRC-063 25 mg, PRC-063 45 mg, PRC-063 70 mg and PRC-063 100 mg.

Who was this study for?

Listed age limits: from 18 years.

Want to explore more studies?

Explore studies